Share on StockTwits
 

Analysts at Jefferies Group raised their price objective on shares of InterMune (NASDAQ:ITMN) from $7.00 to $20.00 in a research report issued to clients and investors on Wednesday, StockRatingsNetwork.com reports. Jefferies Group’s target price would indicate a potential downside of 37.85% from the company’s current price.

InterMune (NASDAQ:ITMN) traded down 14.87% on Wednesday, hitting $32.18. The stock had a trading volume of 9,484,051 shares. InterMune has a 1-year low of $8.61 and a 1-year high of $38.73. The stock has a 50-day moving average of $16.25 and a 200-day moving average of $14.70. The company’s market cap is $2.887 billion. InterMune also saw unusually large options trading on Tuesday. Stock investors purchased 25,056 call options on the company. This represents an increase of approximately 667% compared to the average volume of 3,267 call options.

Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse raised their price target on shares of InterMune from $15.00 to $33.00 in a research note on Wednesday. Separately, analysts at Robert W. Baird raised their price target on shares of InterMune to $44.00 in a research note on Tuesday. Finally, analysts at Oppenheimer raised their price target on shares of InterMune from $19.00 to $42.00 in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $34.00.

InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.